focus -WSS

focus

author：Wikipedia 2025-09-02 22:26:43 - browse：24

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： How to bring more disabled researchers into academia

hotspot

WSS

YouTube cracks down on misinformation on cancer treatment

Sen. Paul opposes bill to ban Chinese biotechs

Biden administration begins canceling student loan debt for 804,000 borrowers

How to bring more disabled researchers into academia

Treatments for cramps don't cut it. Why aren't there better options?

Senators push IRS to launch nonprofit hospital probe

explore

focus

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Sports medicine is finally prioritizing gender equality

Biden administration begins canceling student loan debt for 804,000 borrowers

Sports medicine is finally prioritizing gender equality

Former medical device CEO who sold dummy, plastic parts convicted of fraud

United colonoscopy coverage change 'may cost lives,' doctors say

IVF, abortion rights issues kick off Biden’s State of the Union

United colonoscopy coverage change 'may cost lives,' doctors say

In his State of the Union, Biden takes clear aim at 'Big Pharma'

leisure time

Just how do doctors, lawmakers, and the public define abortion?

YouTube cracks down on misinformation on cancer treatment

NEJM study link tiny plastics in blood vessels to heart problems

Novo Nordisk touts Wegovy study, but still struggling with supply

Illinois Supreme Court finds assault weapons ban constitutional

In his State of the Union, Biden takes clear aim at 'Big Pharma'

entertainment

hotspot

focus

Wikipedia